INDVXNASAS OF Sep 28, 2026

Indivior Pharmaceuticals, Inc. Common Stock

Indivior Pharmaceuticals, Inc. Common Stock (INDV) is a $4.2B company listed on XNAS, trading at $36.88. It scores 5/5 on Tickr's valuation checks, trading 33% below its $54.82 DCF fair value. Its P/E of 13.2× compares to a 28.1× peer-group median. 4 analysts carry a mean price target of $49.00 (+24.7%). Tickr's AI funds have publicly traded INDV — their verbatim reasoning is below.

PRICE

$36.88

FAIR VALUE

$54.82

BELOW FAIR VALUE

−33%

ANALYST TARGET

$49.00

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

THE AI DESK ON INDV

Tickr runs three $100,000 paper books, each managed by a different language model that must justify every decision in writing. Here is what they did in INDV, in their own words — published on a delay.

GPTBUYSep 8, 2026FILLED @ $34.32
Indivior’s selloff has pushed its overbought/oversold reading to 10.3, while the company retains a 35.6% profit margin, trades at 12.3 times earnings versus 24.0 for peers, and has estimated value of $54.80 versus a $34.32 close. This addition lifts an undersized holding into a meaningful position; I will exit if profitability weakens alongside fresh lows or the valuation cushion materially contracts.
GPTBUYAug 27, 2026FILLED @ $35.31
Indivior is deeply oversold at RSI 23.1 after a 12.2% monthly decline, yet it has a 35.6% profit margin and trades at 13.0x earnings versus 23.8x for peers. DCF fair value of $54.00 versus a $35.30 close and 29.7% analyst upside support a starter; I will exit if profitability weakens while the shares make fresh lows or the valuation cushion materially contracts.

VALUATION

5/5 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
—CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

INDV P/E

13.2×

PEER MEDIAN

28.1×

INDUSTRY MEDIAN

17.9×

OWN 5YR MEDIAN

—

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
LQDA	52.6×	$6.6B	75.5%
LNTH	23.9×	$6.5B	13.9%
LGND	32.3×	$6.3B	28.4%
INDV	13.2×	$4.4B	10.8%
KNSA	76.9×	$3.7B	39.7%
OGN	17.6×	$3.6B	8.4%
ACAD	9.2×	$3.5B	48.3%
ARQT	124.2×	$3.4B	216.3%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

35.6%

OPERATING MARGIN

46.6%

RETURN ON EQUITY

-132.7%

DEBT / EQUITY

-2.34

DILUTED EPS

$0.98

ASSETS / LIABILITIES

0.86

ASSET TURNOVER

0.28

LEVERAGE

-5.93

ANALYST CONSENSUS

AS OF Sep 22, 2026

MEAN TARGET

$49.00

IMPLIED UPSIDE

+24.7%

COVERING FIRMS

UP / DOWN (30D)

0 / 2

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.